Elon Musk’s neurotechnology company Neuralink is gearing up to shift from early clinical trials to large-scale production of its brain-computer interface (BCI) chips in 2026, aiming to make the technology far more widely available than it has been so far. The update was announced by Musk in a post shared on the social media platform X.
The company also plans to introduce a largely automated surgical process for implanting the devices, reducing the need for traditional skull-opening surgery by threading ultra-thin electrodes through the brain’s protective membrane without removing bone.
Neuralink’s BCI chips are designed to help people with severe neurological impairments, such as quadriplegia and other paralysis, by translating neural signals into digital commands so users can control computers, browse the internet, play video games or interact with devices purely through thought. By the end of 2025, the company reported that about a dozen people worldwide had received implants during human trials, with participants demonstrating the ability to perform everyday digital tasks using the technology.
The push toward mass production reflects broader progress in Neuralink’s development. In 2025, the company secured $650 million in Series E funding, valuing it at around $9 billion, and received regulatory milestones including approval from U.S. authorities for certain device applications. Expanded automation is central to Neuralink’s strategy, with robotic systems expected to handle most of the implant procedure, aiming to make surgeries faster, more consistent and scalable for future patients.
Neuralink’s growth plan also includes broadening clinical access beyond the United States, with the company conducting its first procedures in countries like Canada and the United Kingdom.
These steps suggest the firm is pushing toward a future where BCI technology moves from experimental use in a handful of cases to high-volume deployment for people with neurological conditions, advancing the frontier of human-machine interaction.
Also Read